Abexinostat is a potent histone deacetylase (HDAC) inhibitor and epigenetic modulator primarily investigated for its therapeutic potential in treating relapsed or refractory multiple myeloma by inducing… Read more
Abexinostat is a potent histone deacetylase (HDAC) inhibitor and epigenetic modulator primarily investigated for its therapeutic potential in treating relapsed or refractory multiple myeloma by inducing apoptosis and cell cycle arrest in malignant cells. This category provides access to high-quality related compounds essential for the rigorous analytical evaluation of the active pharmaceutical ingredient. Pharmaceutical laboratories utilize these abexinostat impurities, metabolites, and stable isotope labelled standards—such as deuterated analogs—for critical tasks including impurity profiling, method validation, and pharmacokinetic studies. By employing these precise reference standards, researchers can ensure accurate quantification and regulatory compliance during the development and quality control of therapeutic formulations. These compounds serve as vital tools for navigating the complex analytical challenges associated with HDAC inhibitor development and ensuring the reliability of downstream experimental results.